This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Human insulin derived from recombinant DNA represents a striking advance in medical technology. Future uses of recombinant DNA technology likely will overshadow human insulin, for only a minority of humans benefit from the latter's availability, while future gains from this technology should benefit everyone.While Miller's discussion (1982; 248:1503) is accurate and appropriate, I seem to detect negative connotations. Most questions about human insulin now are unanswered. Clinical experience encompasses only two years; greater breadth and depth of experience will accumulate over the years. No one yet knows whether long-term therapy with human insulin will substantially benefit the diabetic patient when compared with the use of highly purified animal insulins. However, the possibility does exist that purified homologous insulin, even delivered subcutaneously, will be safer and less immunogenic than any animal insulin. Early reports from clinical studies support the possibility that circulating antibody titers decline when patients
Whitehouse FW. Future of Human Insulin. JAMA. 1983;250(8):1027–1028. doi:10.1001/jama.1983.03340080017016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: